Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome

BJU International

Volumn 108, Issue 8, 2011, Pages 1356-1362

  Hoogland, Agnes Marije ^a   Dahlman, Anna ^c   Vissers, Kees J ^a   Wolters, Tineke ^b   Schröder, Fritz H ^b   Roobol, Monique J ^b   Bjartell, Anders S ^c   Van Leenders, Geert J L H ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

MSP; biomarker; CRISP 3; prognosis; prostate cancer

Indexed keywords

BETA MICROSEMINOPROTEIN; CYSTEINE RICH SECRETORY PROTEIN 3; PROSTATE SPECIFIC ANTIGEN; SECRETORY PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; COHORT ANALYSIS; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NEEDLE BIOPSY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; BIOPSY, NEEDLE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROSTATIC SECRETORY PROTEINS; SALIVARY PROTEINS AND PEPTIDES; SEMINAL PLASMA PROTEINS;

EID: 80053432526     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.10059.x     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49
2. Sorensen KD, Orntoft TF,. Discovery of prostate cancer biomarkers by microarray gene expression profiling. Expert Rev Mol Diagn 2010; 10: 49-64
3. Wolters T, Vissers KJ, Bangma CH, Schroder FH, van Leenders GJ,. The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy. BJU Int 2010; 106: 280-6
4. Donovan MJ, Osman I, Khan FM, et al,. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int 2010; 105: 462-7
5. Freedland SJ, deGregorio F, Sacoolidge JC, et al,. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J Urol 2003; 169: 1325-30 (Pubitemid 36323777)
6. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA,. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007; 13: 7003-11 (Pubitemid 350276881)
7. Kuczyk M, Machtens S,. Predictive value of decreased p27 Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Prostate Cancer Prostatic Dis 1999; 2: S17 (Pubitemid 30058688)
8. Moul JW,. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol 1999; 35: 399-407 (Pubitemid 29229540)
9. Romics I, Banfi G, Szekely E, Krenacs T, Szende B,. Expression of p21(waf1/cip1), p27 (kip1), p63 and androgen receptor in low and high Gleason score prostate cancer. Pathol Oncol Res 2008; 14: 307-11
10. van Leenders GJ, Dukers D, Hessels D, et al,. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 2007; 52: 455-63 (Pubitemid 46963432)
11. Wu TT, Wang JS, Jiaan BP, et al,. Role of p21(WAF1) and p27(KIP1) in predicting biochemical recurrence for organ-confined prostate adenocarcinoma. J Chin Med Assoc 2007; 70: 11-5 (Pubitemid 46218237)
12. Zhang Q, Helfand BT, Jang TL, et al,. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res 2009; 15: 3557-67
13. Bjartell A, Johansson R, Björk T, et al,. Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. Prostate 2006; 66: 591-603
14. Bjartell AS, Al-Ahmadie H, Serio AM, et al,. Association of cysteine-rich secretory protein 3 and β-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res 2007; 13: 4130-8 (Pubitemid 47105975)
15. Udby L, Bjartell A, Malm J, et al,. Characterization and localization of cysteine-rich secretory protein 3 (CRISP-3) in the human male reproductive tract. J Androl 2005; 26: 333-42 (Pubitemid 40628969)
16. Udby L, Calafat J, Sorensen OE, Borregaard N, Kjeldsen L,. Identification of human cysteine-rich secretory protein 3 (CRISP-3) as a matrix protein in a subset of peroxidase-negative granules of neutrophils and in the granules of eosinophils. J Leukoc Biol 2002; 72: 462-9
17. Udby L, Lundwall A, Johnsen AH, et al,. beta-Microseminoprotein binds CRISP-3 in human seminal plasma. Biochem Biophys Res Commun 2005; 333: 555-61 (Pubitemid 40848327)
18. Kosari F, Asmann YW, Cheville JC, Vasmatzis G,. Cysteine-rich secretory protein-3: a potential biomarker for prostate cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 1419-26 (Pubitemid 35340379)
19. Beke L, Nuytten M, Van Eynde A, Beullens M, Bollen M,. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 2007; 26: 4590-5 (Pubitemid 47037047)
20. Cooper CS, Foster CS,. Concepts of epigenetics in prostate cancer development. Br J Cancer 2009; 100: 240-5
21. Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE,. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate 2010; 70: 333-40
22. Yeager M, Deng Z, Boland J, et al,. Comprehensive resequence analysis of a 97 kb region of chromosome 10q11.2 containing the MSMB gene associated with prostate cancer. Hum Genet 2009; July 31 [Epub ahead of print]
23. Kote-Jarai Z, Leongamornlert D, Tymrakiewicz M, et al,. Mutation analysis of the MSMB gene in familial prostate cancer. Br J Cancer 2010; 102: 414-8
24. Roobol MJ, Kirkels WJ, Schroder FH,. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int 2003; 92 (Suppl. 2): 48-54 (Pubitemid 38091140)
25. Epstein JI,. An update of the Gleason grading system. J Urol 2010; 183: 433-40
26. van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH,. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 2007; 52: 1560-3 (Pubitemid 350052404)
27. Schroder FH, Bangma CH,. The European Randomized Study of Screening for Prostate Cancer (ERSPC). Br J Urol 1997; 79 (Suppl. 1): 68-71
28. Abrahamsson PA, Andersson C, Bjork T, et al,. Radioimmunoassay of beta-microseminoprotein, a prostatic-secreted protein present in sera of both men and women. Clin Chem 1989; 35: 1497-503 (Pubitemid 19187853)
29. de Vries SH, Postma R, Raaijmakers R, et al,. Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. Eur Urol 2007; 51: 366-74; discussion 74 (Pubitemid 44937799)
30. Schroder FH, Hugosson J, Roobol M, et al,. Screening and prostate-cancer mortality in a randomized European study. New Engl J Med 2009; 360: 1320-8
31. Draisma G, Boer R, Otto SJ, et al,. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78 (Pubitemid 36833878)
32. Girvan AR, Chang P, van Huizen I, et al,. Increased intratumoral expression of prostate secretory protein of 94 amino acids predicts for worse disease recurrence and progression after radical prostatectomy in patients with prostate cancer. Urology 2005; 65: 719-23 (Pubitemid 40523006)
33. Donovan MJ, Khan FM, Fernandez G, et al,. Personalized prediction of tumor response and cancer progression on prostate needle biopsy. J Urol 2009; 182: 125-32
34. Reeves JR, Dulude H, Panchal C, Daigneault L, Ramnani DM,. Prognostic value of prostate secretory protein of 94 amino acids and its binding protein after radical prostatectomy. Clin Cancer Res 2006; 12: 6018-22 (Pubitemid 44703763)